Oramed Pharmaceuticals plans to price public sale of common shares

Joint bookrunners Aegis Capital and Aegis Capital assist with offering

By Devika Patel

Knoxville, Tenn., June 17 - Oramed Pharmaceuticals Inc. will price a public offering of common stock with a 45-day greenshoe, according to a preliminary prospectus supplement filed Monday with the Securities and Exchange Commission.

Aegis Capital Corp. and Aegis Capital LLC are the joint bookrunning managers.

Proceeds will be used for clinical trials, for research and product development activities and for general corporate purposes, including general working capital purposes.

Based in Jerusalem, Oramed develops oral-delivered treatments for diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.